Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials

Cheng, Lu; Yan, Jing; Han, Shutang; Chen, Qiuhua; Chen, Mingqi; Jiang, Hua; Lu, Jun

doi:10.1186/s13054-019-2427-4

Critical Care

Table 1 Studies designs of included randomized controlled trials

From: Comparative efficacy of vasoactive medications in patients with septic shock: a network meta-analysis of randomized controlled trials

ID	Source	Country	Setting	Male/female	Treatment 1	Treatment 2	Treatment 3	Primary outcome
1	Martin et al. 1993 [32]	France	SC	24/8	Dopamine	Norepinephrine		Hemodynamics status
2	Marik and Mohedin 1994 [33]	USA	SC	11/9	Norepinephrine	Dopamine		Systemic and splanchnic oxygen utilization
3	Levy et al. 1997 [34]	France	SC	21/9	Epinephrine	Norepinephrine/dobutamine		Hemodynamics, lactate metabolism, and gastric tonometric variables
4	Malay et al. 1999 [35]	USA	SC	8/2	Vasopressin	Placebo		Arterial pressure
5	Kern et al. 2001 [36]	Germany	SC	NA	Enoximone	Dobutamine		Hepatosplanchnic function
6	Seguin et al. 2002 [37]	France	SC	12/10	Epinephrine	Norepinephrine/dobutamine		Systemic and pulmonary hemodynamics
7	Patel et al. 2002 [38]	Canada	MC	18/6	Norepinephrine	Vasopressin		Renal function
8	Dünser et al. 2003 [39]	Australia	SC	NA	Arginine vasopressin	Norepinephrine		Differences in hemodynamics
9	Morelli et al. 2005 [40]	Italy	MC	21/7	Dobutamine	Levosimendan		Systemic and regional hemodynamics
10	Albanèse et al. 2005 [41]	France	SC	13/7	Norepinephrine	Terlipressin		MAP
11	Luckner et al. 2006 [42]	Australia	SC	11/7	Vasopressin/norepinephrine	Norepinephrine		Cutaneous vascular reactivity
12	Seguin et al. 2006 [43]	France	SC	17/5	Dopexamine/norepinephrine	Epinephrine		Gastric perfusion
13	Schmoelz et al. 2006 [44]	Germany	SC	35/26	Dopexamine	Dopamine	Placebo	Systemic and renal effects
14	Lauzier et al. 2006 [45]	Canada, France	MC	14/9	Vasopressin	Norepinephrine		Hemodynamic parameters and SOFA score
15	Mathur et al. 2007 [46]	India	SC	32/18	Dopamine	Norepinephrine		Hemodynamic parameters
16	Annane et al. 2007 [47]	France	MC	202/128	Epinephrine	Norepinephrine/dobutamine		28-day all-cause mortality
17	Myburgh et al. 2008 [48]	Australia	MC	167/110	Epinephrine	Norepinephrine		The time taken to achieve a clinician-prescribed MAP goal
18	Morelli et al. 2008 [49]	Italy	SC	43/16	Norepinephrine	Terlipressin/norepinephrine	Terlipressin/dobutamine/norepinephrine	Systemic, pulmonary, and regional hemodynamic measurements and blood gases
19	Morelli et al. 2008 [50]	Italy	SC	21/11	Norepinephrine	Phenylephrine		Hemodynamic parameters
20	Russell et al. 2008 [51]	Canada, Australia, USA	MC	475/304	Norepinephrine	Vasopressin		Death from any cause
21	Morelli et al. 2009 [52]	Italy	SC	21/9	Terlipressin	Norepinephrine	Vasopressin	Systemic and regional hemodynamics
22	Alhashemi et al. 2009 [53]	Saudi Arabia	SC	NA	Levosimendan	Dobutamine		Central venous saturation (ScvO2) and serum lactate
23	De Backer et al. 2010 [54]	Belgium, Austria, Spain	MC	956/723	Dopamine	Norepinephrine		The rate of death at 28 days
24	Jain and Singh 2010 [55]	India	SC	28/26	Norepinephrine	Phenylephrine		Hemodynamic parameters
25	Patel et al. 2010 [56]	USA	SC	116/136	Dopamine	Norepinephrine		All-cause 28-day mortality
26	Morelli et al. 2010 [57]	Italy	SC	27/13	Levosimendan	Dobutamine		Systemic and microvascular hemodynamics
27	Morelli et al. 2011 [58]	Italy	SC	37/23	Terlipressin	Arginine vasopressin	Control	Microcirculatory perfusion
28	Han et al. 2012 [59]	China	MC	99/40	Pituitrin	Norepinephrine		The rate of death at 28 days
29	Mahmoud and Ammar 2012 [60]	Egypt	SC	31/29	Norepinephrine/dobutamine	Norepinephrine/epinephrine		SOFA score and cardiovascular effects
30	Memis et al. 2012 [61]	Turkey	SC	16/14	Dobutamine	Levosimendan		Regional blood flow
31	Mehta et al. 2013 [62]	Canada	MC	85/36	Norepinephrine	Vasopressin		Cardiac biomarkers and electrocardiograms
32	Hua et al. 2013 [63]	China	SC	18/14	Terlipressin	Dopamine		Hemodynamics and oxygenation variables
33	Fang and Dong 2014 [64]	China	SC	27/9	Dobutamine	Levosimendan		Hemodynamics and cardiac function
34	Torraco et al. 2014 [65]	Italy	SC	19/7	Levosimendan	Control		Mitochondrial function
35	Gordon et al. 2016 [66]	UK	MC	238/171	Vasopressin	Norepinephrine		Kidney failure-free days during the 28-day period
36	Xiao et al. 2016 [67]	China	SC	22/10	Norepinephrine	Terlipressin/norepinephrine		Tissue blood flow and organ function
37	Gordon et al. 2016 [68]	UK	MC	289/226	Levosimendan	Placebo		Mean daily SOFA score
38	Meng et al. 2016 [69]	China	SC	24/14	Levosimendan	Dobutamine		Biomarkers of myocardial injury and systemic hemodynamics
39	Barzegar et al. 2016 [70]	Iran	SC	19/11	Norepinephrine	Vasopressin		Lactate level and lactate clearance
40	Choudhury et al. 2016 [71]	India	SC	69/15	Terlipressin	Noradrenaline		Hemodynamics
41	Chen et al. 2017 [72]	China	SC	29/28	Norepinephrine	Terlipressin		Hemodynamics, volume responsiveness
42	Hajjej et al. 2017 [73]	Tunisia	SC	17/3	Levosimendan	Placebo		Cellular metabolism
43	Russell et al. 2017 [8]	Belgium, Denmark, USA	MC	27/21	Selepressin	Placebo		Stabilization of MAP as determined by the proportion of patients maintaining a MAP > 60 mmHg

Back to article page

ISSN: 1364-8535

Contact us

Submission enquiries: journalsubmissions@springernature.com